Best Practices in the Diagnosis and Treatment of Community-Associated Lower Respiratory Tract Conditions
![Switching from intravenous to oral antibiotics in hospitalized patients with community-acquired pneumonia: A real-world analysis 2010–2018 - ScienceDirect Switching from intravenous to oral antibiotics in hospitalized patients with community-acquired pneumonia: A real-world analysis 2010–2018 - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1341321X20301008-gr1.jpg)
Switching from intravenous to oral antibiotics in hospitalized patients with community-acquired pneumonia: A real-world analysis 2010–2018 - ScienceDirect
![Antibiotics | Free Full-Text | Comparison between Ceftriaxone and Sulbactam-Ampicillin as Initial Treatment of Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis Antibiotics | Free Full-Text | Comparison between Ceftriaxone and Sulbactam-Ampicillin as Initial Treatment of Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis](https://www.mdpi.com/antibiotics/antibiotics-11-01291/article_deploy/html/images/antibiotics-11-01291-g001.png)
Antibiotics | Free Full-Text | Comparison between Ceftriaxone and Sulbactam-Ampicillin as Initial Treatment of Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis
![Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance | Critical Care | Full Text Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance | Critical Care | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fcc13095/MediaObjects/13054_2013_Article_3039_Fig1_HTML.jpg)
Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance | Critical Care | Full Text
![Update in Community Acquired Pneumonia (CAP) Treatment: Macrolide Resistance - REBEL EM - Emergency Medicine Blog Update in Community Acquired Pneumonia (CAP) Treatment: Macrolide Resistance - REBEL EM - Emergency Medicine Blog](https://rebelem.com/wp-content/uploads/2018/06/Screen-Shot-2018-05-30-at-1.30.18-AM-1024x512.png)
Update in Community Acquired Pneumonia (CAP) Treatment: Macrolide Resistance - REBEL EM - Emergency Medicine Blog
![Short Course Antibiotics for Peds CAP: A Systematic Review and Meta-Analysis - REBEL EM - Emergency Medicine Blog Short Course Antibiotics for Peds CAP: A Systematic Review and Meta-Analysis - REBEL EM - Emergency Medicine Blog](https://rebelem.com/wp-content/uploads/2022/11/Short-Course-Abx-1024x698.jpg)
Short Course Antibiotics for Peds CAP: A Systematic Review and Meta-Analysis - REBEL EM - Emergency Medicine Blog
![How long should we treat children with pneumonia for? - the results of CAP-IT - Don't Forget the Bubbles How long should we treat children with pneumonia for? - the results of CAP-IT - Don't Forget the Bubbles](https://i0.wp.com/dontforgetthebubbles.com/wp-content/uploads/2021/10/short-blg-posts-cap-it.png?resize=1024%2C1024&ssl=1)
How long should we treat children with pneumonia for? - the results of CAP-IT - Don't Forget the Bubbles
![Impact of Blood Cultures on the Changes of Treatment in Hospitalized Patients with Community-Acquired Pneumonia Impact of Blood Cultures on the Changes of Treatment in Hospitalized Patients with Community-Acquired Pneumonia](https://benthamopen.com/contents/figures/TORMJ/TORMJ-7-60_F1.jpg)
Impact of Blood Cultures on the Changes of Treatment in Hospitalized Patients with Community-Acquired Pneumonia
![Narrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trial - The Lancet Infectious Diseases Narrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/500a0697-3d2b-458b-b806-ba7ac59f6db7/gr1.gif)